, What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy, Int J Radiat Oncol Biol Phys, vol.44, pp.747-748, 1999.
, What hypofractionated protocols should be tested for prostate cancer?, International Journal of Radiation Oncology*Biology*Physics, vol.56, issue.4, pp.1093-1104, 2003.
DOI : 10.1016/S0360-3016(03)00132-9
, Fractionation and protraction for radiotherapy of prostate carcinoma, International Journal of Radiation Oncology*Biology*Physics, vol.43, issue.5, pp.1095-1101, 1999.
DOI : 10.1016/S0360-3016(98)00438-6
, Is the ??/?? Value for Prostate Tumours Low Enough to be Safely Used in Clinical Trials?, Clinical Oncology, vol.19, issue.5, pp.289-301, 2007.
DOI : 10.1016/j.clon.2007.02.007
, Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue
, Is ??/?? for prostate tumors really low?, International Journal of Radiation Oncology*Biology*Physics, vol.50, issue.4, pp.1021-1031, 2001.
DOI : 10.1016/S0360-3016(01)01607-8
, Use of Individual Fraction Size Data from 3756 Patients to Directly Determine the ??/?? Ratio of Prostate Cancer, International Journal of Radiation Oncology*Biology*Physics, vol.68, issue.1, pp.24-33, 2007.
DOI : 10.1016/j.ijrobp.2006.12.036
, High dose rate prostate brachytherapy: the California Endocurietherapy (CET) Method, Radiotherapy and Oncology, vol.57, issue.3, pp.289-296, 2000.
DOI : 10.1016/S0167-8140(00)00291-7
, Higher than standard radiation doses (???72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer, International Journal of Radiation Oncology*Biology*Physics, vol.46, issue.3, pp.567-574, 2000.
DOI : 10.1016/S0360-3016(99)00455-1
, Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont Phase II dose-escalating trial, International Journal of Radiation Oncology*Biology*Physics, vol.47, issue.2, pp.343-352, 2000.
DOI : 10.1016/S0360-3016(00)00436-3
, How low is the ??/?? ratio for prostate cancer?, International Journal of Radiation Oncology*Biology*Physics, vol.55, issue.1, pp.194-203, 2003.
DOI : 10.1016/S0360-3016(02)03828-2
, Hypofractionation for prostate cancer radiotherapy???what are the issues?, International Journal of Radiation Oncology*Biology*Physics, vol.57, issue.4, pp.912-914, 2003.
DOI : 10.1016/S0360-3016(03)01456-1
, Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer, Journal of Clinical Oncology, vol.23, issue.25, pp.6132-6138, 2005.
DOI : 10.1200/JCO.2005.06.153
, The ??/?? ratio for prostate cancer: What is it, really?, Radiotherapy and Oncology, vol.76, issue.1, pp.1-3, 2005.
DOI : 10.1016/j.radonc.2005.06.009
, Determinants of Change in Prostate-Specific Antigen Over Time and Its Association With Recurrence After External Beam Radiation Therapy for Prostate Cancer in Five Large Cohorts, International Journal of Radiation Oncology*Biology*Physics, vol.72, issue.3, pp.782-791, 2008.
DOI : 10.1016/j.ijrobp.2008.01.056
URL : https://hal.archives-ouvertes.fr/inserm-00263863
, Individualized Predictions of Disease Progression Following Radiation Therapy for Prostate Cancer, Journal of Clinical Oncology, vol.23, issue.4, pp.816-825, 2005.
DOI : 10.1200/JCO.2005.12.156
, Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: Findings from a prospective, multi-institutional, phase I/II dose-escalation study, International Journal of Radiation Oncology*Biology*Physics, vol.60, issue.5, pp.1351-1356, 2004.
DOI : 10.1016/j.ijrobp.2004.05.026
, An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk, International Journal of Radiation Oncology*Biology*Physics, vol.65, issue.2, pp.351-357, 2006.
DOI : 10.1016/j.ijrobp.2005.12.007
, Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy, Cancer, vol.72, issue.8, pp.1557-1566, 1999.
DOI : 10.1002/(SICI)1097-0142(19991015)86:8<1557::AID-CNCR24>3.0.CO;2-2
, Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer, International Journal of Radiation Oncology*Biology*Physics, vol.60, issue.4, pp.1082-1087, 2004.
DOI : 10.1016/j.ijrobp.2004.04.048
, Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias, International Journal of Radiation Oncology*Biology*Physics, vol.57, issue.1, pp.11-18, 2003.
DOI : 10.1016/S0360-3016(03)00439-5
, Random-Effects Models for Longitudinal Data, Biometrics, vol.38, issue.4, pp.963-974, 1982.
DOI : 10.2307/2529876
, Phase II Trial of Hypofractionated Image-Guided Intensity-Modulated Radiotherapy for Localized Prostate Adenocarcinoma, International Journal of Radiation Oncology*Biology*Physics, vol.69, issue.4, pp.1084-1089, 2007.
DOI : 10.1016/j.ijrobp.2007.04.049
, The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma, Radiotherapy and Oncology, vol.48, issue.2, pp.203-207, 1998.
DOI : 10.1016/S0167-8140(98)00061-9
, PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis, International Journal of Radiation Oncology*Biology*Physics, vol.64, issue.4, pp.1140-1150, 2006.
DOI : 10.1016/j.ijrobp.2005.07.006